分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

USP9x promotes CD8 + T-cell dysfunction in association with autophagy inhibition in septic liver injury : USP9x inhibits CD8 + T cell autophagy in septic liver injury

Lulu Sheng, Juntao Chen, Yiqing Tong, Yi Zhang, Qiming Feng, Zhenghao Tang

Journal:ACTA BIOCHIMICA ET BIOPHYSICA SINICA

IF:3.51

DOI:10.3724/abbs.2022174

PMID:

Published:2022-11-16

research field:分子生物学免疫学病理生理学

Abstract

Sepsis is a life-threatening condition manifested by concurrent inflammation and immunosuppression. Ubiquitin-specific peptidase 9, X-linked (USP9x), is a USP domain-containing deubiquitinase which is required in T-cell development. In the present study, we investigate whether USP9x plays a role in hepatic CD8 + T-cell dysfunction in septic mice. We find that CD8 + T cells are decreased in the blood of septic patients with liver injury compared with those without liver injury, the CD4/CD8 ratio is increased, and the levels of cytolytic factors, granzyme B and perforin are downregulated. The number of hepatic CD8 + T cells and USP9x expression are both increased 24 h after cecal ligation and puncture-induced sepsis in a mouse model, a pattern similar to liver injury. The mechanism involves promotion of CD8 + T-cell dysfunction by USP9x associated with suppression of cell cytolytic activity via autophagy inhibition, which is reversed by the USP9x inhibitor WP1130. In the in vivo studies, autophagy is significantly increased in hepatic CD8 + T cells of septic mice with conditional knockout of mammalian target of rapamycin. This study shows that USP9x has the potential to be used as a therapeutic target in septic liver injury.

本文使用的Yeasen产品

购物车
客服
转染试用